- ISIN
- US67022C1062
- CUSIP
- 67022C106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 28, 2017
Highlights
- Market Cap
- $6.77M
- Enterprise Value
- -$20.80M
- EPS (TTM)
- -£7.19
- Gross Profit (TTM)
- -£69.48K
- EBITDA (TTM)
- -£22.65M
- Year Range
- $1.33 - $25.58
- ROA (TTM)
- -111.89%
- ROE (TTM)
- -137.83%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NCNA Performance Chart
NuCana plc (NCNA) is down 49.2% since the beginning of the year. At $2 per share, NCNA is trading 92.8% below its 52-week high of $26. Investors who bought $1,000 worth of NCNA shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Returns By Period
NuCana plc (NCNA) has returned -49.17% so far this year and -90.85% over the past 12 months.
NuCana plc
- 1D
- -4.19%
- 1M
- -9.41%
- YTD
- -49.17%
- 6M
- -46.33%
- 1Y
- -90.85%
- 3Y*
- -92.59%
- 5Y*
- -83.37%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
NCNA Monthly Returns History
Based on dividend-adjusted daily data since Sep 28, 2017, NCNA's average daily return is -0.11%, while the average monthly return is -3.79%.
Historically, 29% of months were positive and 71% were negative. The best month was Jul 2022 with a return of +153.8%, while the worst month was May 2025 at -94.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 11 months.
On a daily basis, NCNA closed higher 43% of trading days. The best single day was Aug 19, 2024 with a return of +177.1%, while the worst single day was May 8, 2025 at -65.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -30.28% | -13.94% | -35.19% | 52.14% | 9.39% | -21.46% | -49.17% | ||||||
| 2025 | -14.29% | -4.90% | -10.02% | -32.40% | -94.02% | 62.61% | -25.26% | -62.82% | 45.45% | -13.58% | 6.73% | -15.89% | -98.49% |
| 2024 | 1.39% | 6.70% | -18.75% | -39.08% | -8.84% | -29.36% | 42.75% | 0.55% | -37.16% | -29.57% | -19.75% | -8.46% | -83.91% |
| 2023 | 128.79% | -3.97% | -33.79% | -11.57% | -1.71% | -5.33% | -3.80% | -5.26% | -15.28% | -19.67% | -15.71% | -28.38% | -55.18% |
| 2022 | 19.75% | -5.26% | -63.00% | -29.63% | -16.37% | 23.32% | 153.79% | -21.20% | -27.93% | -4.31% | -14.61% | -22.71% | -72.27% |
| 2021 | 28.73% | -8.65% | -5.49% | -13.03% | -29.49% | -9.48% | -23.47% | 25.47% | -3.01% | -6.20% | 12.81% | -12.82% | -46.99% |
Benchmark Metrics
NuCana plc has an annualized alpha of -33.96%, beta of 1.02, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since September 28, 2017.
- This stock participated in 199.48% of S&P 500 Index downside but only -115.11% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -33.96%
- Beta
- 1.02
- R²
- 0.02
- Upside Capture
- -115.11%
- Downside Capture
- 199.48%
Return for Risk
Risk / Return Rank
NCNA ranks 7 for risk / return — in the bottom 7% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NuCana plc (NCNA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NCNA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.85 | ||
| Sortino ratioReturn per unit of downside risk | -4.89 | ||
| Omega ratioGain probability vs. loss probability | 0.75 | 1.37 | -0.61 |
| Calmar ratioReturn relative to maximum drawdown | -0.98 | 2.78 | -3.77 |
| Martin ratioReturn relative to average drawdown | -1.15 | 12.44 | -13.59 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NuCana plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NuCana plc was 100.00%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current NuCana plc drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -100.00%Mar 2026 | 7y 9mo | — | 8y 18dJun 2018 - now |
2017 bear market2017 | -46.58%Dec 2017 | 2mo 24d | 22d | 3mo 16dOct 2017 - Jan 2018 |
2018 bear market2018 | -38.30%Mar 2018 | 1mo 22d | 19d | 2mo 11dJan 2018 - Apr 2018 |
2018 bear market2018 | -25.39%May 2018 | 28d | 28d | 1mo 26dApr 2018 - Jun 2018 |
2017 pullback2017 | -1.74%Oct 2017 | 0s | 1d | 1dOct 2017 - Oct 2017 |
Drawdown Indicators
| NCNA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -92.60% | -9.10% | -83.50% |
Max Drawdown (3Y)Largest decline over 3 years | -99.97% | -18.90% | -81.07% |
Max Drawdown (5Y)Largest decline over 5 years | -99.99% | -25.43% | -74.56% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -1.80% | -98.20% |
Average DrawdownAverage peak-to-trough decline | -81.10% | -10.71% | -70.39% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 80.75% | 2.03% | +78.72% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NuCana plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NuCana plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NCNA in comparison with other companies in the Biotechnology industry. Currently, NCNA has a P/B value of 0.2. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NCNA
Add NuCana plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NCNA